Tech Company Financing Transactions
Grey Wolf Therapeutics Funding Round
Grey Wolf Therapeutics, based in Abingdon, secured $49 million from Earlybird Venture Capital, Pfizer Venture Investments and Andera Partners.
Transaction Overview
Company Name
Announced On
1/26/2023
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series B
Investors
Earlybird Venture Capital (Lead Investor)
Pfizer Venture Investments (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the continued development of its immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens. This includes the anticipated advancement of lead asset, GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Milton Park Innovation Centre 99 Park Drive, Milton Park
Abingdon, OX14 4RY
UK
Abingdon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and Peter Joyce (CEO; former Project Leader at Vertex Pharmaceuticals).?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Joyce
Co-Founder
Thomas McCarthy
Browse more venture capital transactions:
Prev: 1/26/2023: Redivivus venture capital transaction
Next: 1/26/2023: MIACH Orthopaedics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs